Leica Biosystems, a Danaher company and a global leader in end-to-end anatomic and digital pathology solutions, announced multiple U.S. Food and Drug Adm...
Revvity’s new maternal and fetal biochemistry testing platform Designed for accessibility, simplicity, and flexibility Purpose-built for small...
PacBio (NASDAQ: PACB), developer of the world’s most advanced sequencing technologies, announced the upcoming availability of SPRQ-Nx chemistry and...
CellCarta, a global CRO laboratory supporting the biopharmaceutical industry, announced a strategic collaboration with Tempus AI, Inc. (NASDAQ: TEM). Under...
Global pharmaceutical leader Lupin Limited (Lupin) (BSE: 500257) (NSE: LUPIN) (REUTERS: LUPIN.BO) (BLOOMBERG: LPCIN) announced that it has rec...
Fresenius Kabi, an operating company of the Fresenius Group, is recalling one lot of Tyenne® (tocilizumab-aazg) Injection 400 mg/20 mL (20 mg/mL)20 m...
Award supports an iPSC and AI-driven drug discovery program targeting the leading cause of death in DMD patients Greenstone Biosciences, a biote...
Biogen Inc. announced the completion of the acquisition of RayThera Inc., a privately held biotechnology company focused on discovering and developing sm...
Bone Biologics is developing a targeted approach to bone regeneration through its proprietary NELL-1 platform, designed to address the li...
Adults Taking ORZEYFUL Experienced Significant and Meaningful Improvements Across the Full Range of Symptoms of Narcolepsy Type 1 (NT1) in Clinical T...
Basilea Pharmaceutica Ltd, Allschwil (SIX: BSLN), a commercial-stage biopharmaceutical company committed to meeting the needs of patients with severe bac...
Following the introduction of Invenia™ ABUS Prime at the Society of Breast Imaging Annual Symposium, the installation at BeSound in Los Angeles...
Pathos assumes responsibility for early clinical development of AZD4241, utilizing its AI-driven Foundry platform to drive patient stratification and t...
Nurix Therapeutics, Inc. announced that the first patient has been enrolled in the global Phase 3 DAYBreak CLL-306 study (NCT07516093) evaluating b...
© 2026 Biopharma Boardroom. All Rights Reserved.
